Multiple-Center Retrospective Study of Severe and Critical COVID-19 in Shanghai
NCT ID: NCT05422963
Last Updated: 2022-06-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2022-06-10
2023-06-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2)
NCT05244330
Real World Study of Classic Infectious Disease
NCT04020536
CA-MRSA Infection in China: Epidemiology, Molecular Characteristics, Treatment, and Outcome
NCT03064464
Incidence, Associated Factors, and Burden of Post COVID-19 Condition in Brazil
NCT05822193
Risks of Bacterial and Fungal Superinfection in Patients With COVID-19
NCT05256316
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. To analyze the relationship between the clinical characteristics and their clinical prognosis;
3. To analyze the relationship between clinical intervention and their clinical prognosis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
severe and critical COVID-19
1. hospital admission time more than 24 hours
2. meet the standard of definition of severe and critical COVID-19 in "Diagnosis and Treatment Plan for new Coronavirus Pneumonia (Ninth Edition)"
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* admission time more than 24 hours
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erzhen Chen, PhD
Role: PRINCIPAL_INVESTIGATOR
Ruijin Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruijin Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCCS-2022-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.